HIGHLIGHTS
- who: Benjamin Kelmendi and M.D. from the and/or honoraria from Oxford University Press and Elsevier, and has filed a patent on the use ofYale School of Medicine, Department of Psychiatry, New Haven, CT, USA have published the Article: Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report, in the Journal: (JOURNAL)
- what: The authors report the experiences of an early participant in this trial who experienced rapid and lasting improvement.
- future: In sum while the observations in this case are promising careful further work is needed. Integrating psychedelic . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.